Drugs / GSK257049
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT00436007 | Apr 2007 → Sep 2008 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00380393 | Jan 2007 → Aug 2008 | malaria | GlaxoSmithKline | Completed | Met primary |
| Phase 2 | NCT00323622 | Apr 2005 → May 2007 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 33 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT02207816 | Sep 2014 → Jan 2017 | malaria | GlaxoSmithKline | Completed | Missed primary |
| Phase 3 | NCT01323972 | May → Nov 2011 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00866619 | Mar 2009 → Mar 2011 | malaria | GlaxoSmithKline | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK 257049 | “Male or female subjects between 5 and 17 months of age at the time of first vaccination received 3 doses of GSK257049 vaccine administered intramuscularly in the left deltoid...” NCT00380393 ↗5“Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine” NCT00323622 ↗ “received 3 doses of the GSK 257049 vaccine from the commercial scale lot 1” NCT01323972 ↗ “received 3 doses of GSK257049 malaria vaccine” NCT02207816 ↗ “GSK257049 malaria vaccine” NCT00866619 ↗ |
| Known as | 257049 | “The purpose of this study is to show the consistency of different lots of a candidate vaccine (257049) against malaria developed by GlaxoSmithKline (GSK) Biologicals.” NCT01323972 ↗1“Candidate Malaria Vaccine (257049) Against Malaria Disease Caused by P. Falciparum Infection in Infants and Children in Africa.” NCT00866619 ↗ |
| Known as | RTS,S/AS02A | “The RTS,S/AS02A vaccine (or GSK 257049 vaccine), GSK Biologicals' candidate Plasmodium falciparum (P. falciparum) malaria vaccine is being developed for the routine...” NCT00323622 ↗ |
| Modality | Vaccine | “GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049” NCT00323622 ↗ |
| Route | Intramuscular | “received 3 doses of GSK257049 vaccine administered intramuscularly in the left deltoid muscle” NCT00380393 ↗ |